echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Abbott/Watson's domestic mRNA vaccine launches phase III clinical trials in China

    Abbott/Watson's domestic mRNA vaccine launches phase III clinical trials in China

    • Last Update: 2021-08-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Text | pick up shells

    On July 21, Watson Biologics registered a phase III clinical trial of mRNA vaccine ARCoVaX (ARCoV) on the China Clinical Trial Network, which is the first phase III clinical trial of a domestic mRNA vaccine


    The study will recruit 2,000 subjects in China, 500 with placebo, and 1,500 in the 15ug/0.


    ARCoVaX was originally developed by Abbio.


    Abbio is mainly responsible for the pre-clinical research of mRNA vaccines, and is responsible for the preparation of clinical application samples, clinical phase I and clinical phase II samples, and technology transfer


    ARCoVaX is encapsulated by lipid nanoparticles (LNPs) and targets the RBD region of the SARS-CoV-2 spike protein


    The vaccine was launched in a phase III clinical study abroad in May this year, and 28,000 subjects are planned to be recruited


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.